On May 30, Sinopharm Group China Biology stated that the first batch of quadrivalent influenza virus split vaccine produced by Shanghai Institute of Biological Products obtained the batch issuance certificate on May 29. Approved for listing.
Inoculation with quadrivalent influenza virus split vaccine is one of the most effective ways to prevent influenza. The quadrivalent influenza virus split vaccine produced by Shanghai Institute of Biological Products adopts the 2022- Development of influenza strains for the 2023 influenza season, including 2 strains of type A virus and 2 strains of type B virus. The launch of this variety will play an active role in the prevention and control of influenza in my country and help to further meet the needs of the people for vaccination.
Recently, the internationally renowned medical journal “Nature” published a study conducted among medical staff by Weill Cornell Medical College in Qatar. It was found that influenza vaccination was associated with a significant reduction in the risk of SARS-CoV-2 infection and the severity of COVID-19, and was 29.7% protective against the new coronavirus 14 days after influenza vaccination, with a protective efficacy of approximately six weeks. In addition, the flu vaccine was 88.9 percent effective against severe, critical or fatal COVID-19 symptoms. The results of this study have aroused widespread concern in China, and the public’s attention to influenza has been brought forward from the autumn and winter of previous years to the present.
Influenza is an acute respiratory infectious disease. Influenza virus easily mutates and spreads rapidly, causing seasonal epidemics every year. There are about 1 billion cases worldwide each year, 3-5 million severe cases, 290,000-650,000 respiratory disease-related deaths, and the case fatality rate is 0.1%-0.2%. Influenza vaccination is the most economical and effective intervention for influenza prevention and control. Infants, school students, pregnant women, and elderly people over 60 years old and other high-risk groups of influenza should be recommended for vaccination.